Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 11/2012

01-11-2012 | Review

Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics

Author: Masato Nagino

Published in: Journal of Gastroenterology | Issue 11/2012

Login to get access

Abstract

Perihilar cholangiocarcinomas are defined anatomically as “tumors that are located in the extrahepatic biliary tree proximal to the origin of the cystic duct”. However, as the boundary between the extrahepatic and intrahepatic bile ducts is not well defined, perihilar cholangiocarcinomas potentially include two types of tumors: one is the “extrahepatic” type, which arises from the large hilar bile duct, and the other is the “intrahepatic” type, which has an intrahepatic component with the invasion of the hepatic hilus. The new TNM staging system published by the International Union Against Cancer (UICC) has been well revised with regard to perihilar cholangiocarcinoma, but it still lacks stratification of patient prognosis and has little applicability for assessing the feasibility of surgical treatment; therefore, further refinement is essential. Most patients with perihilar cholangiocarcinomas present with jaundice, and preoperative biliary drainage is mandatory. Previously, percutaneous transhepatic biliary drainage was used in many centers; however, it is accepted that endoscopic naso-biliary drainage is the most suitable method of preoperative drainage. Portal vein embolization is now widely used as a presurgical treatment for patients undergoing an extended hepatectomy to minimize postoperative liver dysfunction. The surgical resection of a perihilar cholangiocarcinoma is technically demanding and continues to be the most difficult challenge for hepatobiliary surgeons. Because of advances in diagnostic and surgical techniques, surgical outcomes and survival rates after resection have steadily improved. However, survival, especially for patients with lymph node metastasis, is still unsatisfactory, and the establishment of adjuvant chemotherapy is necessary. Further synergy of endoscopists, radiologists, oncologists, and surgeons is required to conquer this intractable disease.
Literature
1.
International Union Against Cancer (UICC). TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.
2.
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62.PubMedCrossRef
3.
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumor. Ann Surg. 1996;224:463–73.PubMedCrossRef
4.
Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808–19.PubMedCrossRef
5.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS, et al. Staging, respectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.PubMedCrossRef
6.
Capussotti L, Muratore A, Polastri R, Ferrero A, Massucco P. Liver resection for hilar cholangiocarcinoma: in hospital mortality and long-term survival. J Am Coll Surg. 2002;195:641–7.PubMedCrossRef
7.
Kawarada Y, Das BC, Naganuma T, Tabata M, Taoka H. Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies. J Gastrointest Surg. 2002;6:617–24.PubMedCrossRef
8.
Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T, et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg. 2003;238:73–83.PubMed
9.
Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg. 2003;238:84–92.PubMed
10.
IJitsma A, Appeltans B, deJong K, Porte R, Peeters P, Slooff M, et al. Extrahepatic bile duct resection in combination with liver resection for hilar cholangiocarcinoma: a report of 42 cases. J Gastrointest Surg. 2004;8:686–94.PubMedCrossRef
11.
Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240:95–101.PubMedCrossRef
12.
Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005;241:693–702.PubMedCrossRef
13.
Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S, Kosuge T. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006;244:240–7.PubMedCrossRef
14.
Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery. 2007;141:581–8.PubMedCrossRef
15.
Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asian experiences. J Hepatobiliary Pancreat Surg. 2010;17:476–89.CrossRef
16.
van Gulik TM, Kloek JJ, Ruys AT, Busch ORC, van Tienhoven GJ, Lameris JS, et al. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37:65–71.PubMedCrossRef
17.
Young AL, Igami T, Senda Y, Adair R, Farid S, Toogood G, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western center demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB. 2011;13:483–93.PubMedCrossRef
18.
Saxena A, Chua T, Chu F, Morris DL. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg. 2011;202:310–20.PubMedCrossRef
19.
Cannon R, Brock G, Buell JF. Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB. 2012;14:142–9.PubMedCrossRef
20.
Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg. 1990;14:535–44.PubMedCrossRef
21.
Nimura Y, Hayakawa N, Kamiya J, Maeda S, Kondo S, Yasui A, et al. Combined portal vein and liver resection for carcinoma of the biliary tract. Br J Surg. 1991;78:727–31.PubMedCrossRef
22.
Nimura Y, Hayakawa N, Kamiya J, Maeda S, Kondo S, Yasui A, et al. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology. 1991;38:170–5.PubMed
23.
Sakamoto E, Nimura Y, Hayakawa N, Kamiya S, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–11.PubMedCrossRef
24.
Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233:385–92.PubMedCrossRef
25.
Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg. 2003;238:720–7.PubMedCrossRef
26.
Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y. Anatomic right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg. 2006;243:28–32.PubMedCrossRef
27.
Ikeyama T, Nagino M, Oda K, Ebata T, Nishio H, Nimura Y. Surgical approach to Bismuth type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases. Ann Surg. 2007;246:1052–7.PubMedCrossRef
28.
Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg. 2009;249:296–302.PubMedCrossRef
29.
Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115–23.PubMedCrossRef
30.
Natsume S, Ebata T, Yokoyama Y, Igami T, Sugawara G, Shimoyama Y, et al. Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and comparison with left hepatectomy. Ann Surg. 2012;255:754–62.PubMedCrossRef
31.
Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.
32.
Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single center 34-year review of 574 consecutive resections. Ann Surg. 2012 (in press).
33.
Nakanuma Y, Curado MP, Franceschi S, Gores G, Paradis V, Sripa B, et al. Intrahepatic cholangiocarcinoma. WHO classification of tumor of the digestive system. 4th ed. Lyon: IARC; 2010.
34.
Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. Am J Med. 1965;38:241–56.PubMedCrossRef
35.
Okuda K, Kubo Y, Okazaki N, Arishima T, Hashimoto M. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer. 1977;39:232–46.PubMedCrossRef
36.
Yamanaka N, Okamoto E, Ando T, Oriyama T, Fujimoto J, Furukawa K, et al. Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer. 1995;76:2449–56.PubMedCrossRef
37.
Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M. The concept of perihilar cholangiocarcinoma is valid. Br J Surg. 2009;96:926–34.PubMedCrossRef
38.
Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–22.PubMedCrossRef
39.
International Union Against Cancer (UICC). TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
40.
Patel T. Cholangiocarcinoma—controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189–200.PubMedCrossRef
41.
Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg. 2012 (in press).
42.
Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140:170–6.PubMed
43.
Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215:31–8.PubMedCrossRef
44.
DeOliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011;53:1363–71.PubMedCrossRef
45.
Nagino M. Perihilar cholangiocarcinoma: a much needed but imperfect new staging system. Nat Rev Gastroenterol Hepatol. 2011;8:252–3.PubMed
46.
Nishio H, Nagino M, Nimura Y. Value of percutaneous transhepatic portography before hepatectomy for hilar cholangiocarcinoma. Br J Surg. 1999;86:1415–21.PubMedCrossRef
47.
Lee HY, Kim SH, Lee JM, Kim SW, Jang JY, Han JK, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology. 2006;239:113–21.PubMedCrossRef
48.
Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. AM J Surg. 2007;193:702–6.PubMedCrossRef
49.
Okumoto T, Sato A, Yamada T, Takase K, Matsuhashi T, Tsuda M, et al. Correct diagnosis of vascular encasement and longitudinal extension of hilar cholangiocarcinoma by four-channel multidetector-row computed tomography. Tohoku J Exp Med. 2009;217:1–8.PubMedCrossRef
50.
Sugiura T, Nishio H, Nagino M, Senda Y, Ebata T, Yokoyama Y, et al. Value of multidetector-row computed tomography in diagnosis of portal vein invasion by perihilar cholangiocarcinoma. World J Surg. 2008;32:1478–84.PubMedCrossRef
51.
Fukami Y, Ebata T, Yokoyama Y, Igami G, Sugawara G, Takahashi Y, et al. Diagnostic ability of MDCT to assess right hepatic artery invasion by perihilar cholangiocarcinoma with left-sided predominance. J Hepatobiliary Pancreat Sci. 2012;19:179–86.PubMedCrossRef
52.
Yoshioka Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. “Supraportal” right hepatic artery: an anatomic trap in hepatobiliary and transplant surgery. World J Surg. 2011;35:1340–4.PubMedCrossRef
53.
Senda Y, Nishio H, Oda K, Yokoyama Y, Ebata T, Igami T, et al. Value of multidetector-row CT in the assessment of longitudinal extension of cholangiocarcinoma: correlation between MDCT and microscopic findings. World J Surg. 2009;33:1459–67.PubMedCrossRef
54.
Noji T, Kondo S, Hirano S, Tanaka E, Suzuki O, Shichinohe T. Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg. 2008;95:92–6.PubMedCrossRef
55.
56.
Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with 18F fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029–35.PubMedCrossRef
57.
Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047–54.PubMedCrossRef
58.
Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010;45:560–6.PubMedCrossRef
59.
Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–51.PubMedCrossRef
60.
Nimura Y, Shionoya S, Hayakawa N, Kamiya J, Kondo S, Yasui A. Value of percutaneous transhepatic cholangioscopy (PTCS). Surg Endosc. 1988;2:213–9.PubMedCrossRef
61.
Nimura Y. Staging of biliary carcinoma: cholangiography and cholangioscopy. Endoscopy. 1993;25:76–80.PubMedCrossRef
62.
De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L, et al. Tissue sampling at ERCP in suspected malignant biliary stricture (Part 1). Gastrointest Endosc. 2002;56:552–61.PubMedCrossRef
63.
De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L, et al. Tissue sampling at ERCP in suspected malignant biliary stricture (Part 2). Gastrointest Endosc. 2002;56:720–30.PubMedCrossRef
64.
Kawashima H, Itoh A, Ohno E, Gotoh H, Hirooka Y. Transpapillary biliary forceps biopsy to distinguish benign biliary stricture form malignancy: how many tissue samples should be obtained? Dig Endosc. 2012;24:22–7.PubMedCrossRef
65.
Fukuda Y, Tsuyuguchi T, Sakai Y, Tsuchiya S, Saisyo H. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc. 2005;62:374–82.PubMedCrossRef
66.
Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging. Gastrointest Endosc. 2007;66:730–6.PubMedCrossRef
67.
Takada T, Hanyu F, Kobayashi S, Uchida Y. Percutaneous transhepatic cholangial drainage: direct approach under fluoroscopic control. J Surg Oncol. 1976;8:83–97.PubMedCrossRef
68.
Nagino M, Hayakawa N, Nimura Y, Dohke M, Kitagawa S. Percutaneous transhepatic biliary drainage in patients with malignant biliary obstruction of the hepatic confluence. Hepatogastroenterology. 1992;39:296–300.PubMed
69.
Nimura Y, Kamiya J, Kondo S, Nagino M, Kanai M. Technique of inserting multiple biliary drains and management. Hepatogastroenterology. 1992;42:323–31.
70.
Maguchi H, Takahashi K, Katanuma A, Osanai M, Nakahara K, Matuzaki S, et al. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:441–6.PubMedCrossRef
71.
Arakura N, Takayama M, Ozaki Y, Maruyama M, Chou Y, Kodama R, et al. Efficacy of preoperative endoscopic nasobiliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2009;16:473–7.PubMedCrossRef
72.
Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol. 2011;46:242–8.PubMedCrossRef
73.
Kawashima H, Itoh A, Ohno E, Itoh Y, Ebata T, Nagino M, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications. Ann Surg. 2012 (in press).
74.
Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg. 2010;97:1860–6.PubMedCrossRef
75.
Hwang S, Song GW, Ha TY, Lee YJ, Kim KH, Ahn CS, et al. Reappraisal of percutaneous transhepatic biliary drainage tract recurrence after resection of perihilar bile duct cancer. World J Surg. 2012;36:379–85.PubMedCrossRef
76.
Kanai M, Nimura Y, Kamiya J, Kondo S, Nagino M, Miyachi M, et al. Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery. 1996;119:498–504.PubMedCrossRef
77.
Liu CL, Lo CM, Lai EC, Fan ST. Endoscopic retrograde cholangiopancreatography and endoscopic endoprosthesis insertion in patients with Klatskin tumors. Arch Surg. 1998;133:293–6.PubMedCrossRef
78.
Gerhards MF, den Hartog D, Rauws EA, van Gulik TM, Gonzalez D, Lameris JS, et al. Palliative treatment in patients with unresectable hilar cholangiocarcinoma: results of endoscopic drainage in patients with type III and IV hilar cholangiocarcinoma. Eur J Surg. 2001;167:274–80.PubMedCrossRef
79.
Vibert E, Farges O, Regimbeau JM, Belghiti J. Benign hilar biliary strictures stented with metallic stents can be resected by using an oncologic approach. Surgery. 2005;137:506–10.PubMedCrossRef
80.
Lytras D, Olde Damink SW, Amin Z, Imber CJ, Malago M, et al. Radical surgery in the presence of biliary metallic stents: revising the palliative scenario. J Gastrointest Surg. 2011;15:489–95.PubMedCrossRef
81.
Makuuchi M, Takayasu K, Takuma T, Yamazaki S, Hasegawa H, Nishiura S, et al. Preoperative transcatheter embolization of the portal venous branch for patients receiving extended lobectomy due to the bile duct carcinoma. J Jpn Soc Clin Surg. 1984;45:14–20. (in Japanese).
82.
Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, et al. Preoperative portal embolization to increase safety major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107:521–7.PubMed
83.
Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803–8.PubMedCrossRef
84.
Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;244:524–35.
85.
Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M. Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg. 2012;29:23–9.PubMedCrossRef
86.
Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, Miyagawa S, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology. 1999;29:1099–105.PubMedCrossRef
87.
Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176–81.PubMed
88.
Nagino M, Nimura Y, Hayakawa N. Percutaneous transhepatic portal embolization using newly devised catheters. World J Surg. 1993;17:520–4.PubMedCrossRef
89.
Nagino M, Nimura Y, Kamiya J, Kondo S, Kanai M. Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Radiology. 1996;200:559–63.PubMed
90.
Nagino M, Nimura Y, Kamiya J, Kondo S, Uesaka K, Kin Y, et al. Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma. Surgery. 1995;117:677–81.PubMedCrossRef
91.
Nagino M, Kamiya J, Kanai M, Uesaka K, Sano T, Yamamoto H, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery. 2000;127:155–60.PubMedCrossRef
92.
Nagino M, Kanai M, Morioka A, Yamamoto H, Kawabata Y, Hayakawa N, et al. Portal and arterial embolization before extensive liver resection in patients with markedly poor functional reserve. J Vasc Interv Radiol. 2000;11:1063–8.PubMedCrossRef
93.
Nagino M, Nimura Y, Kamiya J, Kondo S, Uesaka K, Kin Y, et al. Changes in hepatic lobe volume in biliary tract carcinoma patients after right portal vein embolization. Hepatology. 1995;21:434–9.PubMed
94.
Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization; an appraisal by biliary indocyanine green excretion. Ann Surg. 1996;223:77–83.PubMedCrossRef
95.
Goto Y, Nagino M, Nimura Y. Doppler estimation of portal blood flow after percutaneous transhepatic portal vein embolization. Ann Surg. 1998;228:209–13.PubMedCrossRef
96.
Nagino M, Nimura Y, Kamiya J, Kanai M, Hayakawa N, Yamamoto H. Immediate increase in arterial blood flow in embolized hepatic segments after portal vein embolization: CT demonstration. Am J Roentgenol. 1998;171:1037–9.CrossRef
97.
Kito Y, Nagino M, Nimura Y. Doppler evaluation of hepatic arterial blood flow velocity after percutaneous transhepatic portal vein embolization. Am J Roentgenol. 2001;176:909–12.CrossRef
98.
Madoff DC, Makuuchi M, Nagino M, Vauthey JN, editors. Venous embolization of the liver. Springer, London, 2011.
99.
Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol. 2005;16:215–25.PubMedCrossRef
100.
de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol. 2010;17:2081–9.PubMedCrossRef
101.
Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001;88:165–75.PubMedCrossRef
102.
Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208–17.PubMed
103.
Cherqui D, Benoist S, Malassagne B, Humeres R, Rodriguez V, Fagniez PL. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg. 2000;135:302–8.PubMedCrossRef
104.
Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg. 2010;97:1260–8.PubMedCrossRef
105.
Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann Surg. 2010;251:281–6.PubMedCrossRef
106.
Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, et al. Oncologic superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012;19:1602–8.PubMedCrossRef
107.
Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K. No-touch resection of hilar malignancies with right hepatectomy and routine portal reconstruction. J Hepatobiliary Pancreat Surg. 2009;16:502–7.PubMedCrossRef
108.
Ota T, Araida T, Yamamoto M, Takasaki K. Operative outcome and problems of right hepatic lobectomy with pancreatoduodenectomy for advanced carcinoma of the biliary tract. J Hepatobiliary Pancreat Surg. 2007;14:155–8.PubMedCrossRef
109.
Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ, Prasad KR, et al. Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol. 2008;34:787–94.PubMedCrossRef
110.
Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center’s experience. Am J Surg. 2008;196:160–9.PubMedCrossRef
111.
Sakamoto Y, Sano T, Shimada K, Kosuge T, Kimata Y, Sakuraba M, et al. Clinical significance of reconstruction of the right hepatic artery for biliary malignancy. Langenbeck’s Arch Surg. 2006;391:203–8.CrossRef
112.
Yamanaka N, Yasui C, Yamanaka J, Ando T, Kuroda N, Maeda S, et al. Left hemihepatectomy with microsurgical reconstruction of the right-sided hepatic vasculature: a strategy for preserving hepatic function in patients with proximal bile duct cancer. Langenbeck’s Arch Surg. 2001;386:364–8.CrossRef
113.
Shimada H, Endo I, Sugita M, Masunari H, Fujii Y, Tanaka K, et al. Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg. 2003;27:1137–42.PubMedCrossRef
114.
Takasaki K, Kobayashi S, Mutoh H, Akimoto S, Toda I, Asado S, et al. Our experiences (5 cases) of extended right lobectomy combined with pancreato-duodenectomy for the carcinoma of the gall bladder (in Japanese). Tan to Sui. 1980;1:923–32.
115.
Tsukada K, Yoshida K, Aono T, Koyama S, Shirai Y, Uchida K, et al. Major hepatectomy and pancreatoduodenectomy for advanced carcinoma of the biliary tract. Br J Surg. 1994;81:108–10.PubMedCrossRef
116.
Kaneoka Y, Yamaguchi A, Isogai M, Kumda T. Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy. World J Surg. 2010;34:2662–70.PubMedCrossRef
117.
Hemming AW, Magliocca JF, Fujita S, Kayler LK, Hochwald S, Zendejas I, et al. Combined resection of the liver and pancreas for malignancy. J Am Coll Surg. 2010;210:808–16.PubMedCrossRef
118.
Miwa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, et al. Is major hepatectomy with pancreatoduodenectomy justified for advanced biliary malignancy? J Hepatobiliary Pancreat Surg. 2007;14:136–41.PubMedCrossRef
119.
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010;23:692–7.PubMedCrossRef
120.
Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreatobiliary carcinoma. Cancer. 2002;95:1685–95.PubMedCrossRef
121.
Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57:647–53.PubMedCrossRef
122.
Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GEMOX study. Ann Oncol. 2004;15:1339–43.PubMedCrossRef
123.
Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101:578–86.PubMedCrossRef
124.
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91:1769–74.PubMedCrossRef
125.
Valle J, Wasan H, Palner DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.PubMedCrossRef
126.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74.PubMedCrossRef
127.
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009;250:950–6.PubMedCrossRef
128.
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg. 2009;13:1470–9.PubMedCrossRef
129.
Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, et al. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg. 2012;256:288–96.
130.
Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17:449–54.PubMedCrossRef
131.
Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010;17:455–62.PubMedCrossRef
132.
Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:463–9.PubMedCrossRef
133.
Miyazaki M, Kimura F, Shimizu H, Yoshidome H, Otuka M, Kato A, et al. One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci. 2010;17:470–5.PubMedCrossRef
134.
Young AL, Prasad KR, Toogood GJ, Lodge PA. Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centers, Leeds. J Hepatobiliary Pancreat Sci. 2010;17:497–504.PubMedCrossRef
135.
Rocha FG, Matsuo K, Blumgart LH, Jarnagin WR. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Sci. 2010;17:490–6.PubMedCrossRef
Metadata
Title
Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics
Author
Masato Nagino
Publication date
01-11-2012
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 11/2012
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0628-6

Other articles of this Issue 11/2012

Journal of Gastroenterology 11/2012 Go to the issue

Original Article—Alimentary Tract

Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial

Original Article—Liver, Pancreas, and Biliary Tract

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C

Original Article—Liver, Pancreas, and Biliary Tract

One- and two-step self-expandable metal stent placement for distal malignant biliary obstruction: a propensity analysis

Original Article—Liver, Pancreas, and Biliary Tract

Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease

Original Article—Liver, Pancreas, and Biliary Tract

Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?

Original Article—Alimentary Tract

Endocrine cells in human fetal corpus of stomach: appearance, distribution, and density
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits